Vipidia (alogliptin benzoate)
- Region
- 🇪🇺 EU
- Active substance
- alogliptin benzoate
- Company
- Takeda Pharma A/S
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Wed 18 Sep 2013
- Application
- EMEA/H/C/002182
- ATC
- A10BH04
- Official record
- www.ema.europa.eu
Indication
Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
Regulatory milestones
No milestones recorded in the last year.
Follow Vipidia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.